Lung density associates with survival in Alpha 1 antitrypsin deficient patients by Green, Clara et al.
 
 
Lung density associates with survival in Alpha 1
antitrypsin deficient patients
Green, Clara; Parr, D.g.; Edgar, Ross; Stockley, R.a.; Turner, Alice
DOI:
10.1016/j.rmed.2016.01.007
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Green, C, Parr, DG, Edgar, R, Stockley, RA & Turner, A 2016, 'Lung density associates with survival in Alpha 1
antitrypsin deficient patients', Respiratory Medicine, vol. 112, pp. 81-87.
https://doi.org/10.1016/j.rmed.2016.01.007
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
After an embargo period this document is available under a CC-BY-NC-ND license
Checked Feb 2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Accepted Manuscript
Lung density associates with survival in Alpha 1 antitrypsin deficient patients
C.E. Green, D.G. Parr, R.G. Edgar, R.A. Stockley, A.M. Turner
PII: S0954-6111(16)30004-X
DOI: 10.1016/j.rmed.2016.01.007
Reference: YRMED 4841
To appear in: Respiratory Medicine
Received Date: 30 October 2015
Revised Date: 14 January 2016
Accepted Date: 16 January 2016
Please cite this article as: Green C, Parr D, Edgar R, Stockley R, Turner A, Lung density associates
with survival in Alpha 1 antitrypsin deficient patients, Respiratory Medicine (2016), doi: 10.1016/
j.rmed.2016.01.007.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
LUNG DENSITY ASSOCIATES WITH SURVIVAL IN ALPHA 1 
ANTITRYPSIN DEFICIENT PATIENTS 
 
CE Green1, DG Parr2, RG Edgar3, RA Stockley3, AM Turner1 
1. Centre for Translational Inflammation Research, University of Birmingham, 
Birmingham, B152WB, United Kingdom (UK) 
2. University Hospitals Coventry and Warwickshire, Clifford Bridge Road, Coventry, 
UK 
3. University Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham, B15 
2GW, UK 
Corresponding Author: C E Green, address as above; email clara.green@nhs.net 
Key words: Chronic obstructive pulmonary disease, Alpha 1 antitrypsin deficiency, 
Quality of life, Survival 
Word count: 2851 
Abstract word count: 200  
Conflict of interest statement: AMT’s institution has received grants from the Alpha 1 
Foundation, which is partially funded by manufacturers of A1AT augmentation therapy, and has 
a future grant from Grifols Biotherapeutics. AMT and RAS head the UK A1ATD registry, which 
has received grants from both Grifols Biotherapeutics and CSL Behring. DGP has had previous 
research funding from Grifols Biotherapeutics, and has consulted for CSL Behring. CEG and RGE 
have no conflicts to declare.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
Funding: AMT is currently funded by the Alpha 1 Foundation and Linde REAL Fund. CEG is 
funded by the West Midlands Chest Fund. The UK registry has received unconditional funds 
from Grifols Biotherapeutics and CSL Behring. 
 
ABSTRACT 
Introduction 
CT density correlates with quality of life (QOL) scores and impaired upper zone lung 
density associates with higher mortality in alpha one antitrypsin deficiency (A1ATD).  
We hypothesised that decline in CT densitometry would relate to survival or 
deterioration in QOL in A1ATD. 
Methods 
All augmentation naïve PiZZ patients in the UK A1ATD registry with ≥two successive 
quantitative CT scans were selected. Patients were divided into groups based on CT 
density decline and the relationship to survival and change in QOL compared by 
univariate analyses and multivariate Cox regression. Analyses were performed for 
whole lung, upper zone and lower zone density separately. Exploratory analyses of 
FEV1 subgroups were conducted. 
Results 
110 patients were identified; 77 had whole lung and lung zone density recorded on two 
CT scans, 33 patients had upper zone data only on four scans. Decline in lower zone 
density associated with survival, even after adjustment for baseline lung density 
(p=0·048), however upper zone density and whole lung density decline did not. This 
difference appeared to be driven by those with FEV1 >30% predicted.  
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Conclusion 
Rate of change in lung densitometry could predict survival in A1ATD. 
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INTRODUCTION 
Alpha-1-Antitrypsin Deficiency (A1ATD) is a genetically determined anti-proteinase 
deficiency predisposing to emphysema[1]. Patients classically have rapidly progressive 
emphysema and thus reduced life expectancy[2]. Factors predicting mortality in 
untreated A1ATD include FEV1, gas transfer(Kco) and lung density[2]. Rapid FEV1 
decline occurs with higher baseline FEV1 and frequent exacerbations, whereas Kco 
decline is greatest in patients with severe airflow obstruction[3, 4]. 
Observational studies have suggested that emphysema progression in A1ATD may be 
slowed by augmentation therapy[5], which is recommended for use in non-smoking 
patients with FEV1 35-60% predicted in the USA/Europe[6] and 25-80% predicted in 
Canada[7], in the presence of emphysema on CT scan. However, an influence on FEV1 
decline is difficult to prove because it is a poor surrogate of emphysema, thus more 
patients are needed to detect change in randomised controlled trials (RCTs), with 
consequent cost and logistic implications. Trials of augmentation have therefore been 
powered to detect decline in CT densitometry which allows for a more reasonable 
sample size[8-10], and a properly powered study has recently confirmed its beneficial 
effect on this outcome measure[11]. However CT density is not yet used routinely in 
clinical practice to assess A1ATD patients. 
We hypothesised that the rate of decline in CT density would relate to subsequent 
survival in patients who had never received augmentation therapy (augmentation 
naive) A1ATD patients. We chose to analyze density decline in patient groups (no 
decline versus decline) rather than using a continuous outcome as we felt this would be 
more meaningful for clinical decision making, such as selection for augmentation 
therapy.  
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MATERIALS AND METHODS 
Patients 
The UK A1ATD registry assessment and follow up procedures are described elsewhere; 
all patients gave informed consent and studies were approved by the local ethics 
committee[4]. In brief it was established in 1996, and is still running; patients continue 
follow up annually in the stable state until death or withdrawal. This study therefore 
represents a retrospective analysis of prospectively collected data. All augmentation 
naive patients with ≥two quantitative CT scans prior to 2010 were selected and 
subsequent deaths and lung transplants noted. Patients with whole lung, as well as 
upper and lower zone density measurements recorded were included. Follow up time 
was defined as time from determination of decline (e.g. second CT scan date) to date of 
analysis (censored at 31/12/2012). 
CT scan analysis 
All scans were done in the stable state, for research purposes, a median of two years 
apart (range 0·9-3·3) between 2002-2005, the protocol being described in our previous 
work, and measuring density at total lung capacity (TLC)[12]. Whole lung density was 
measured as the 15th percentile lung density (PD15), calculated from the frequency 
histogram of lung voxels at -910HU and defined as the density threshold of the lowest 
15% of voxels, as described in our previous work[9, 13]. Density is calculated as g/l by 
adding 1000 to the PD15. Total decline in lung density and time between scans 
determined the annual rate of decline per patient. In the 77 patients who had two scans 
regression analysis across time points to calculate decline was not possible. In the 33 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
patients who had four scans we used the first and last scans only to calculate decline in 
order to ensure that methods were identical for both groups. 
Statistical analysis 
All analyses were undertaken in SPSS® (version 20; IBM, USA). Firstly, we examined the 
relationship between decline in CT density and lung physiology by comparing the 
proportion of patients in different CT decline categories to patients with/without a 
significant decline in lung function (defined as faster than normal aging, i.e. a 
deteriorating % predicted). Next, univariate analyses compared patients with declining 
density to those not declining, and those alive without transplantation to those who 
died, using t-tests (normally distributed data), Mann-Whitney-U-tests (non-normally 
distributed data) or Chi square tests (frequency variables). Multivariate analysis was 
then performed using Cox regression. Variables with univariate p<0.15 were considered 
for inclusion in multivariate analysis, up to a maximum of one covariate/ten deaths. 
[14] All analyses are reported one-tailed since there was a clear one way hypothesis (i.e. 
lung density decline would associate with reduced survival). Finally the primary test 
cohort in whom lower zone data was available, were sub-stratified by FEV1 <30%, 30-
50% and >50% predicted, prior to analyses as before. 
 
RESULTS 
110 patients were identified; 77 had whole, upper and lower zone lung density 
recorded on 2 CT scans from our current scanner using the same software; one patient 
had received a lung transplant and was excluded for the main analysis. Of the 
remainder, 9 had their scans as part of the placebo arm of EXACTLE[10] and the others 
as part of observational study protocols or clinical care. A further 33 patients had upper 
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zone data from a previously used  scanner and were analysed separately; one patient 
from the previous dataset was also scanned this way, thus n=34 for this replication 
dataset. Five of these patients had also received lung transplants and were excluded 
from analysis. (Figure1) None were current smokers; mean pack year exposure was 
17·1 (SEM 1·7). Table one shows patient characteristics. 
CT data 
available 
Whole, upper & lower zone lung 
density group 
Upper zone lung density only 
group 
 Status 
N(%) 
All 
76 
Alive 
49 (64.5) 
Dead 
27 (35.5) 
p 
value 
All 
29 
Alive 
12 
(41.4) 
Dead 
17 (58.6) 
p 
value 
Male patients 44 (57.9) 28 (63.6) 16 (36.4) 0.858 22 (75.9) 10 (83.3) 12 (70.6) 0.333 
Age (years ) 52.1 
(14.8) 
50.8 
(18.2) 
56.0 
(10.8) 
0.003 52.5 (8.6) 52.3 
(10.3) 
52.5 (6.8) 0.195 
Median follow up 
(years) 
7.2 (1.6) 8.3 (0.9) 5.7 (4.4) <0.001 9.5 (6.4) 13.5 
(0.5) 
7.8 (3.2) <0.001 
FEV1 (% 
predicted) 
45.3 
(29.6) 
50.1 
(39.6) 
36.9 
(24.5) 
0.011 33.6 
(35.9) 
57.8 
(38.3) 
24.2 
(14.1) 
0.001 
FEV1/FVC 34.0 
(23.0) 
35.0 
(29.5) 
33.0 
(14.3) 
0.051 38.6 
(30.6) 
55.7 
(38.4) 
30.7 
(20.2) 
0.003 
DLCO (% 
predicted) 
64.9 
(38.4) 
70.7 
(36.6) 
53.9 
(45.3) 
0.029 86.7 
(26.1) 
90.6 
(12.1) 
69.3 
(30.2) 
0.038 
KCO (% 
predicted) 
60.5 
(28.3) 
62.6 
(28.8) 
59.5 
(26.8) 
0.113 71.2 
(23.6) 
78.9 
(18.1) 
67.2 
(33.3) 
0.075 
Chronic 
bronchitis 
31 (40.8) 15 (30.6) 16 (59.3) 0.015 14 (48.3) 6 (50.0) 8 (47.1) 0.438 
Baseline density 
(g/l) 
46.2 
(28.7) 
55.4 
(54.9) 
39.8 
(18.2) 
0.002  -   -   -   -  
Change in 
density/year 
-2.13 
(4.08) 
-2.89 
(6.07) 
-2.08 
(2.76) 
0.501  -   -   -   -  
Density declining 65 (85.8) 42 (85.7) 23 (85.2) 0.293  -   -   -   -  
UZ density 30.33 
(26.49) 
30.65 
(25.94) 
26.53 
(28.86) 
0.981 57.50 
(35.45) 
65.4 
(31.35) 
55.65 
(35.67) 
0.135 
LZ density 49.29 
(27.58) 
48.91 
(31.33) 
49.31 
(32.10) 
0.671  -   -   -   -  
UZ density 
decline/year 
-1.72 
(3.03) 
-1.57 
(3.14) 
-2.06 
(3.97) 
0.051 -1.74 
(2.90) 
-2.03 
(3.89) 
-1.52 
(2.66) 
0.069 
LZ density 
decline/year 
-1.45 
(5.28) 
-0.94 
(4.37) 
-3.41 
(5.26) 
0.025  -   -   -   -  
UZ density 
declining 
54 (77.1) 33 (71.7) 21(87.5) 0.115 17 (50.0) 6 (35.3) 11(64.7) 0.364 
LZ density 52 (74.3) 31 (67.4) 21 (87.5) 0.058  -   -   -   -  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
declining 
SGRQ 44.6 
(31.2) 
39.1 
(24.4) 
54.6 
(22.2) 
0.001 61.8 
(31.1) 
49.5 
(40.3) 
66.8 
(20.1) 
0.010 
 
Table 1: Clinical characteristics 
The table shows characteristics of the cohort, stratified by survivor status, and the 
univariate test statistics comparing survivors with those who died. Frequency data is 
shown as n (%), and is in italics. Scale variables are shown in normal type as median 
(IQR). Significant differences between survivors and those that died are shown by a 
bold type p value. UZ = upper zone, LZ=lower zone. Density decline/year measured as 
change in whole lung density; UZ and LZ density decline defined as a deterioration in 
density in the upper or lower third of the lung respectively (all at -910HU). Chronic 
bronchitis was defined using the MRC definition[15]. 
 
Relationship of CT density decline to other clinical features 
Whole lung CT density decline occurred in 57.2% of patients whose FEV1 did not 
decline any faster than normal aging (i.e. remained at the same % predicted), compared 
to 42.8 of those with declining FEV1. More marked differences occurred when 
considering density by lung zone (Figure 2a). Most patients with no decline in KCO or 
DLCO also exhibited no decline in CT density, a pattern that was maintained across zones 
(Figure 2b & 2c). Consequently, decline in KCO and DLCO had a higher sensitivity than 
FEV1 decline to predict CT density decline (see table 2).  
Density decline in upper and lower zone correlated reasonably well (σ=0·62, 
p<0·0001), however 31% of patients who exhibited no deterioration in their upper zone 
had a decline in their lower zone density and 13% of patients whose lower zone was 
stable had a decline in upper zone density. 
Patients with no decline in the lower zone exhibited no significant difference in age, 
FEV1, DLCO, pack years smoked, degree of bronchodilator reversibility, prevalence of 
chronic bronchitis[15] or emphysema from those whose lower zone was declining (all 
p>0·17). Those with no decline in the upper zone were slightly younger (47·3 v 53·1 
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years, p=0·03) and had better baseline lung density in both upper and lower zones 
(p=0·022 and 0·015 respectively), but exhibited no other significant physiological or 
demographic differences (all p>0·36) from those whose upper zone was deteriorating. 
Decline in lung 
function (faster 
than normal 
ageing) 
Sensitivity (%) Specificity (%) Positive 
predictive value 
(%) 
Negative 
predictive value 
(%) 
FEV1 44 91 96 23 
KCO 76 50 89 29 
DLCO 84 25 88 20 
Table 2: The ability of lung function decline to predict CT density decline 
The table shows the sensitivity, specificity and predictive values for FEV1, DLCO and 
KCO decline to predict CT density decline 
 
Survival 
In the whole lung density cohort 27 patients died during follow up. Table 1 shows 
univariate comparisons of survivors compared to those who died. Upper and lower 
zone density decline had p<0·15 hence were appropriate to take forward to Cox 
regression (unlike whole lung density). Only one co-variate could be included due to 
low numbers of deaths; we therefore chose baseline density as this was the most 
strongly associated difference between survivors and those who died. Cox regression 
demonstrated that baseline density (p=0·029) and lower zone density decline 
(p=0·048) were associated with subsequent death, whilst patients whose upper zone 
density was declining showed a similar trend, albeit non-significant (p=0·072). Kaplan-
Meier plots are shown in figure 2. We also assessed a composite outcome of ‘death or 
transplant’, however since this only added one case to the group the result did not 
change appreciably. 
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Similar analyses were performed using the upper zone density measurement group, 
excluding 5 transplanted patients. Table one shows demographics and univariate 
analyses. There was no association between decline in upper zone densitometry and 
survival hence progression to multivariate analysis was inappropriate. Addition of the 5 
transplanted subjects and assessment of the composite measure ‘death or transplant’ 
did not change the results. 
Impact of starting lung function 
Since there was a difference in lung function between survivors and those who died, 
addition of FEV1 as a co-variate would not have been meaningful due to high 
correlation with baseline density (r=0.66, p<0.0001). However, we sub stratified the 
group by FEV1 and repeated the survival analysis for three sub-groups: FEV1 < 30%, 
30-50% and >50% predicted. The analysis was undertaken primarily using lower zone 
density decline, as this was significant in the initial multivariate model. We also 
repeated the analysis using whole lung density decline, because whole lung density has 
been the outcome measure used in augmentation trials, and augmentation is currently 
recommended based in part on FEV1. There were relatively few deaths per subgroup, 
hence to maximise power and minimize risk of type I error[16] we restricted the 
number of variables in the model; CT density decline alone was included as there were 
<20 deaths/subgroup. In patients with FEV1 <30%, neither lower zone CT density 
(p=0·255) nor whole lung density (p=0·286) decline associated with survival.  In 
patients with FEV1 30-50% lower zone decline in densitometry showed an apparent 
trend toward poor survival, at least visually, though this was not statistically significant 
for lower or whole lung density decline (Figure 4a & 4c). In patients with FEV1 >50% 
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lower zone CT density decline related to death (p=0·024; Figure 4b) but whole lung 
density did not (p=0·198; Figure 4d).  
We recognize that there are conflicting views regarding power and covariates in 
regression analyses[17], hence an analysis containing all potential covariates allowable 
in a more lenient method is shown in the supplement.  
 
DISCUSSION 
We have demonstrated that change in lower zone lung CT densitometry relates to 
survival in A1ATD, and that measurement of FEV1 and gas transfer alone will not 
identify all patients who have declining lung density.  
Our main aim was to determine whether change in CT density relates to survival. CT 
density has been the primary outcome measure for RCTs of augmentation therapy in 
A1ATD, as it is more sensitive to change than other outcomes[10].  However 
densitometry was considered an insufficiently validated outcome with reference to 
‘hard’ outcomes like survival and QOL in a key systematic review of augmentation[18]. 
Survival and QOL have obvious relevance to cost-effectiveness models incorporating 
quality adjusted life years (QALYs). Of these, mortality was the most important input 
factor in a recent comparison of economic modeling methods in a lifetime model of 
usual COPD[19], and was our focus.  
We divided our patients into two groups for each measure of CT density: no decline and 
decline. Arguably this could reduce power to show associations between density decline 
rate and outcome, however we chose this method because a key reason underlying our 
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study was the desire to find a threshold that would aid decision making. In most areas 
of clinical practice a specific threshold is used to define deviation from normality, and in 
the absence of a known normal value for CT density decline in health, no decline seemed 
a reasonable threshold to choose. An alternative approach could have been analysis of 
decline greater than the average compared to less than the average. The disadvantage of 
this is that the two groups potentially become similar to one another, whereas our 
approach effectively selects the more unusual patient (no decline) as a comparator. This 
ought to have greater power to detect differences because it uses an extreme 
phenotype. Mortality was lower in patients with no decline in their lower zone, whether 
using our threshold or when using it as a quantitative variable (supplement). 
Augmentation therapy typically results in a slowing of CT density change approaching 
1g/l/year[9-11] in whole lung density, but the effect varies according to the region 
scanned, being most marked in the lower zone[20]. The magnitude of the difference in 
whole lung density decline between survivors and those who died was less than the 
difference in density that augmentation typically provides, suggesting that 
augmentation might improve survival, though this has not been confirmed in trials to 
date. This is not surprising as augmentation trials have only been up to three years in 
duration, and it is apparent from our Kaplan-Meier plots that deaths were generally 
occurring beyond this time. Analysis of matched treated v untreated cohorts with long 
follow up durations may be a way to confirm this in future. However our results suggest 
that lower zone density change is a better surrogate outcome for long term mortality 
than the whole lung density used in augmentation RCTs.  
We also found that upper zone density decline is less relevant to mortality in A1ATD 
than our previous cross-sectional results suggested[2]. Contrary to intuitive thinking 
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about A1ATD lung disease, which is recognized mainly in the lower zone, and which we 
might surmise then progresses to the upper zone, we have previously published a 
model demonstrating that upper zone change may be an early phenomenon[21]. We 
have also observed that FEV1 relates more to lower zone disease, whilst gas transfer 
reflects upper zone disease better [12], and that FEV1 decline typically occurs most 
early in disease, with gas transfer decline being more rapid in those with lower FEV1[4]. 
The densitometry data presented here suggests that upper and lower zone disease may 
progress independently in some patients, at least over the period of time we observed, 
perhaps accounting for these apparent inconsistencies. Repeating the analysis in an 
independent cohort would be necessary to clarify this further. 
Subgroup analyses based on FEV1 showed an apparent separation of curves on Kaplan 
Meier plots suggesting that there may be an effect on mortality in the patients with a 
presentation FEV1>30% predicted. However, this was not statistically significant 
presumably due to inadequate power, as the number of deaths per group was low. We 
took a conservative statistical approach, consistent with classical teaching to include no 
more than one variable per ten events[22], aimed at maximizing power and minimizing 
bias, although arguments can be presented for taking a broader statistical approach[16]. 
However, our results are consistent with past trials and observational work, suggesting 
that this group consists of those most likely to show an augmentation effect[10, 23]. Gas 
transfer declines most rapidly when FEV1 is <30%[4], suggesting that emphysema is 
still progressing at this point. This is supported by previous studies which 
demonstrated that lung density declines at a similar rate in patients with FEV1 < and > 
30%.[16] hence it would be logical to expect an augmentation effect on density decline, 
indicative of reduced progression, to associate with better survival even at this level. 
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This was, however, not the case in our lower zone analyses, perhaps because this region 
links more to FEV1 than gas transfer in A1ATD[12], or because all patients at this poor 
level of lung function have a high risk of death, regardless of whether densitometry is 
still declining.  
Finally, we considered whether lung function decline was a good enough surrogate for 
CT density decline to use in clinical practice. Around half of patients who exhibited no 
significant decline in FEV1 (i.e. normal aging) had whole lung CT density decline. Thus 
use of serial spirometry to select patients most likely to benefit from augmentation 
would miss many at risk individuals. Serial gas transfer would be a more reliable 
marker of the emphysema process detected by density change, but would still miss 
around 20% of patients with a declining CT scan. (Figure 2b,c) Importantly, we have 
also shown that some patients do not decline at all, at least over the period we 
monitored density, but none of the standard measures taken in clinical practice 
differentiated them clearly from decliners. This suggests that serial CT densitometry, 
would be the most reliable way to identify progressing high risk A1ATD patients for 
more aggressive treatment (i.e. augmentation) and lower risk A1ATD patients who 
could safely be monitored. However such decisions would not be simple and it is likely 
that CT density would add to the other lung function features, exacerbation history and 
symptom burden, rather than being viewed as the sole factor to determine treatment 
prescription. The relatively good sensitivity of DLCO decline to predict CT decline, albeit 
with poor specificity, together with the opposite pattern for FEV1 sensitivity and 
specificity highlights this. However, if we were to move to routine use of densitometry 
hospitals/clinics would either need to buy software and train staff, or commission 
services from external providers of CT studies and analysis to ensure consistency and 
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accuracy. Access to different technology may also make standardization across different 
countries difficult to achieve although this has been possible in clinical trials. 
The main strength of our study is its’ ability to link the primary outcome used in clinical 
trials of augmentation (lung densitometry) to a key clinical long term effect, namely 
survival. The main limitation is the number of patients with serial densitometry carried 
out sufficiently long ago to allow meaningful survival analysis. However, the size of our 
primary cohort (n=76) is close in size to the placebo group of the RAPID trial[11] of 
augmentation, and equal to the number enrolled in EXACTLE[10] (the two most recent 
RCTs of augmentation therapy for A1ATD) and thus is comparable in the field. The 
larger sub-group used a protocol which is equivalent to that used in augmentation trials, 
so we believe our findings are robust and generalisable. Finally, we did not have 
prospectively collected exacerbation diary data on all patients (exacerbation history 
was gained by recall at each stable state visit), thus we could not adequately account for 
exacerbations in our analyses. However, over the time between scans it is unlikely that 
exacerbations would have a large impact on CT density decline. 
CONCLUSION  
We have shown that change in CT densitometry is a valid surrogate outcome measure 
for survival in A1ATD. There is potential for clinical usage to bring A1ATD management 
closer to a personalized, risk-based approach. 
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FIGURE LEGENDS 
Figure 1: Flow diagram demonstrating the selection of patients for further analysis 
 
Figure 2: Relationship between decline in CT density and decline in lung function 
a) FEV1 
b) KCO  
c) DLCO  
Each chart shows patients whose % predicted was not changing (normal aging) and those with 
decline greater than normal aging (a falling % predicted), split into CT density decline groups. 
Many patients with an FEV1 that suggested only normal aging had CT density decline (p=0.043). 
Gas transfer measurement was better at detecting density decline, and there was no difference 
in the distribution of density and KCO decline (p=0.120) or DLCO decline (0.514). 
 
Figure 3: Kaplan-Meier plots showing the impact of decline in density in upper and lower zone 
on survival 
In each plot the dashed line indicates declining CT density, and the solid line no decline. 
Censored cases are marked by solid symbols (circles in the no decline group, squares in 
declining patients). Statistics were computed using log rank tests. 
a) Lower zone p=0.048 
b) Upper zone p=0.072 
 
Figure 3: Kaplan-Meier plots stratified by starting FEV1 showing the impact of decline in lower 
and whole lung density on survival 
The dashed lines represent declining density, and solid symbols censored cases, as before. 
a) Lower zone, FEV1 30-50% predicted p=0.292 
b) Lower zone, FEV1 >50% predicted p=0.024 
c) Whole lung, FEV1 30-50% predicted p=0.171 
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d) Whole lung, FEV1 >50% predicted p=0.198 
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FIGURE LEGENDS 
Figure 1: Flow diagram demonstrating the selection of patients for further analysis 
 
Figure 2: Relationship between decline in CT density and decline in lung function 
a) FEV1 
b) KCO  
c) DLCO  
Each chart shows patients whose % predicted was not changing (normal aging) and those with 
decline greater than normal aging (a falling % predicted), split into CT density decline groups. 
Many patients with an FEV1 that suggested only normal aging had CT density decline (p=0.043). 
Gas transfer measurement was better at detecting density decline, and there was no difference 
in the distribution of density and KCO decline (p=0.120) or DLCO decline (0.514). 
 
Figure 3: Kaplan-Meier plots showing the impact of decline in density in upper and lower zone 
on survival 
In each plot the dashed line indicates declining CT density, and the solid line no decline. 
Censored cases are marked by solid symbols (circles in the no decline group, squares in 
declining patients). Statistics were computed using log rank tests. 
a) Lower zone p=0.048 
b) Upper zone p=0.072 
 
Figure 4: Kaplan-Meier plots stratified by starting FEV1 showing the impact of decline in lower 
and whole lung density on survival 
The dashed lines represent declining density, and solid symbols censored cases, as before. 
a) Lower zone, FEV1 30-50% predicted p=0.292 
b) Lower zone, FEV1 >50% predicted p=0.024 
c) Whole lung, FEV1 30-50% predicted p=0.171 
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• Lower zone lung density associates with survival in alpha 1 antitrypsin deficient 
patients. 
 
• Decline in upper zone density and whole lung density does not associate with survival. 
 
• This difference appears to be driven by patients with FEV1>30% predicted. 
